Entered the strategic alliance with the Rhein Biotech in Netherlands (vaccine
...sector)
Entered the strategic alliance with the Fresenius Kabi in Germany (Green Cross
...Corporation was newly launched as the 'Fresenius Kabi Green Cross')
Established the 'Green Cross Venture Investment', a bioventure capital investment
...corporation
Completed the joint venture plant in Pyeongyang, North Korea (Jeongseong Green
...Cross Pharmaceutical Center)
 
   
Switched into a holding company system for the first time in the national listed
...companies
Took over the SangA Pharmaceutical Co., Ltd.
Brought medicines manufactured at the joint venture plant in Pyeongyang for the
...first time in the country
Received the 'Korea Management Award (Best Organization Award)' by the Korea
...Management Association
Green Cross Vaccine achieved USD 30 million of exportation with vaccine, a
...single item (National record as a single finished medicine)

   
Took over the bio-venture corporations including 'Biosapogen' and 'Biomedlab' to
...improve the R&D competence
Established the 'Green Cross International Inc.', a local corporation in the U.S.A.
...as a stepping stone to advance to the home of the biotechnology and the
...healthcare industry
Entered the strategic alliance with Gambro in Sweden
As the Berna Biotech, a Swiss vaccine company, merged and acquired the Dutch
...Rhein Biotech, Green Cross Vaccine became a subsidiary of the Berna Biotech
Changed the category of business into the 'Professional/Scientific and Technical
...Service' in stocks according to the revenue structure changed when switching
...into a holding company.
Chairman Youngsup Huh received the '2nd Korean CEO Award'
   
   
Established the 'Green Cross Life Insurance' by taking over the Daeshin Life
...Insurance in the manner of P&A for the total healthcare business
Merged the SangA Pharmaceutical Co, Green Cross BT and Green Cross LS
Started the cord blood bank business
Launched the 'Tals (Cosmetics for atopic skin)' using the biotechnology
Entered the sales agreement with the 'Korea Johnson & Johnson Medical' to
...distribute the blood glucose meter to the domestic clinics and hospitals

   
Entered into contract with Jaseng Hospital of Oriental Medicine for joint
  development of natural product-based drugs
Acquired the CE Mark for a diagnostic reagent for detection of the hepatitis B virus
Organized the Green Cross Social Service Corps, and opened a week-end farm
Launched blood circulation activator tablets ¡®Berast '
Launched new drug formulation for hiperlipemia ¡®Lipidil Supra '
Launched non-drowsy drug for coryza ¡®Nocol-S'
Green Cross MS launched home medical devices utilizing the concept of ¡®Ubiquity'
Merged Green Cross Sang-A and Green Cross PBM
Changed company name from Green Cross Corporation to Green Cross Holdings
Changed the company name from Green Cross Sang-A to Green Cross Corporation
Launched non-insulin-dependent remedy for diabetes ¡®Amagreen '
Began sale of combined pen-type insulin agent ¡®Novomix 30'
Launched upgraded cosmetics for sensitive skin ¡®TALS Plus'

   

Cord Blood Bank in the Mogam Biotechnology Research Institute acquired
  an ISO 9001:2000 certification from the TUV in Germany
Mogam Biotechnology Research Institute was appointed by the WHO as
  one of collaborating centers in the sector of vaccines and diagnostic reagents
The launch of Zenol Top, a cataplasm patch with no adhesive sheet required
¡®Joint Glucosamin¡¯ for arthritis was launched
Locally Produced Placenta-based Injection 'Laennec' Launched
Green Cross Signs Agreement with Jeollanam-do Bio Industry
  Promotion Foundation to Build Influenza Vaccine Materials Production
  Base (Plans Construction of Influenza Vaccine Materials Factory at
  Hwasun,Jeonnam)



   

Mogam Biotechnology Research Institute, signed a collaborative research
  agreement for anti-cancer protein ¡®Greenstatin¡¯ with MD Anderson cancer center.
Introducing the high quality anti-smoking supplement, Nicopatch
Technology for osteoporosis Treatment, PTH, exported to German company
  BDD/CCDRD Group in the amount of 130 million Euro.
Green Cross and MBRI develop a new genetic anti-cancer medicine
  suppressing generation of new blood vessels by cancer cells.
Tals Plus atopic skincare awarded ¡®Korea¡¯s Leading Brand Grand
  Prize¡¯ as selected directly by consumers.
Green Cross concluded a contract with Biocryst Corp. which supplies
  AI cure ¡®Peramivir¡¯ more powerful than Tamiflu.
- GCC- Bioleaders completed BL (Biosafety level) 3 Class AI Vaccine
  Research Center.
GCMS introduced a diagnosis reagent containing magnetic components in Korea.
Concluded the joint research and domestic executive supply agreement
  with Jennerex in the U.S.A with reference to JX-594 of anti-cancer gene
  therapeutics using vaccine virus
Concluded the global joint development and domestic executive supply
  agreement with Octoplus in the Netherlands with reference to OP-145 of chronic
  tympanitis therapeutics
Ground-breaking for a vaccine factory (which is the influenza vaccine
  raw material production infrastructure) in Hwasun, Jeollanamdo. Realized the
  world¡¯s 12th influenza vaccine self-sufficiency.
Concluded the MOU for the joint R&D of cardiac muscle regeneration cell
  therapeutics with BHK. The development of cell therapeutic was started in earnest.



   

Marketed ¡®Zenol Hottex¡¯ which is a poultice exclusively used for
  lumbago for the first time in Korea
¡°Free Medicare Happiness Sharing¡± Campaign kick off by Green Cross,
  Samsung Seoul Hospital, and Maeil Daily Economic Newspaper
Green Cross EM builds Vietnam¡¯s largest gene recombination vaccine factory
Launched Fursultamin, active vitamin B1 injection for fatigue
Green Cross signed mutual cooperation MOU with Zydus Cadila, India
Quarterly sales hit 100 billion won mark for the first time
Green Cross Life Insurance launches variable universal insurance
Joint development contract signed with Takara Bio, Japan for immuno cell
  treatment medicine
Latest Medical Science Dictionary awarded outstanding book prize by Korea
  National Academy of Science
Contract signed with Abraxis BioScience, USA for exclusive sales of
   anti-cancer medicine Abraxane in Korea and for exclusive sales of five
   biomedicines (under development by Green Cross) in North America
Smallpox vaccine exported to Croatia, an Eastern Europe country for the first time



   

Green Cell Center opened as the most advanced cell process center.
Green Cross Integrated Research Lab explores 3-dimensional structure of blood
  coagulation Factor VIII gene for the first time in the world
  (Published in Feb. issue of 'BLOOD', the most authoritative journal in blood
  research)
Green Cross introduces Hansaplast, Europe's No. 1 first-aid gauze bandage
Green Cross launches MegaGreen, vitamin C injections and Neopecia,
  male-pattern hair loss remedy
KFDA approves phase I clinical trial of Hepabig-Gene, new genetically
  recombined antibiotic drug. Plans to develop world-first genetically recombined
  hepatitis B antibiotic medicine.